Oxford BioTherapeutics Licenses WuXi Biologics' WuXiBody Platform for Five Bispecific Antibodies
Shots:
- Wuxi to receive upfront- $450M milestone and royalties on sales from Oxford BioTherapeutics. Oxford to get rights for WuXi Biologics’ WuXiBody platform to develop and commercialize five Bispecific Abs for cancer
- The focus of the agreement is to develop cancer therapies by combining WuXiBody platform with PDL1 Ab with reduction in cost & risk rates
- WuXiBody platform is a bispecific Ab technology with structural flexibility- assess in development of Abs with different valency (2- 3 or 4 binding sites) for multiple therapeutic area
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
